Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
25 May 2021
25 May 2021
Historique:
received:
17
02
2020
accepted:
19
04
2021
entrez:
26
5
2021
pubmed:
27
5
2021
medline:
27
5
2021
Statut:
epublish
Résumé
Ductal carcinoma in situ (DCIS) is a risk factor for the subsequent development of invasive breast cancer. High-risk features include age <45 years, size >5 cm, high-grade, palpable mass, hormone receptor negativity, and HER2 positivity. We have previously shown that immune infiltrates are positively associated with these high-risk features, suggesting that manipulating the immune microenvironment in high-risk DCIS could potentially alter disease progression. Patients with high-risk DCIS were enrolled in this 3 × 3 phase 1 dose-escalation pilot study of 2, 4, and 8 mg intralesional injections of the PD-1 immune checkpoint inhibitor, pembrolizumab. Study participants received two intralesional injections, three weeks apart, prior to surgery. Tissue from pre-treatment biopsies and post-treatment surgical resections was analyzed using multiplex immunofluorescence (mIF) staining for various immune cell populations. The intralesional injections were easily administered and well-tolerated. mIF analyses demonstrated significant increases in total T cell and CD8
Identifiants
pubmed: 34035311
doi: 10.1038/s41523-021-00267-z
pii: 10.1038/s41523-021-00267-z
pmc: PMC8149838
doi:
Types de publication
Journal Article
Langues
eng
Pagination
59Subventions
Organisme : NCI NIH HHS
ID : T32 CA251070
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA196406
Pays : United States
Références
Clin Cancer Res. 2017 Sep 1;23(17):5210-5217
pubmed: 28611201
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Immunother. 2013 Jan;36(1):29-40
pubmed: 23211623
Radiology. 2012 Jun;263(3):663-72
pubmed: 22623692
Expert Opin Biol Ther. 2014 Oct;14(10):1411-25
pubmed: 24934899
Breast Cancer Res Treat. 2017 Jan;161(1):17-28
pubmed: 27785654
Clin Cancer Res. 2015 Mar 1;21(5):1127-38
pubmed: 25142145
Mod Pathol. 2018 Jul;31(7):1012-1025
pubmed: 29463884
Clin Cancer Res. 2019 Apr 1;25(7):2144-2154
pubmed: 30647082
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
BMC Cancer. 2018 Feb 3;18(1):129
pubmed: 29394917
PLoS One. 2013 Oct 29;8(10):e79114
pubmed: 24205370
Oncoimmunology. 2014 Jan 1;3(1):e27614
pubmed: 24701377
JAMA Oncol. 2020 May 1;6(5):676-684
pubmed: 32053137
Methods. 2014 Nov;70(1):46-58
pubmed: 25242720
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
Breast Cancer Res Treat. 2010 Sep;123(2):397-404
pubmed: 19949854
NPJ Breast Cancer. 2021 May 25;7(1):59
pubmed: 34035311
Mod Pathol. 2018 Aug;31(8):1226-1236
pubmed: 29559742
J Clin Invest. 2013 Jun;123(6):2447-63
pubmed: 23728179
J Immunother. 2008 Jun;31(5):520-7
pubmed: 18463532
Cancer Discov. 2012 Jul;2(7):608-23
pubmed: 22719018
Neoplasia. 2006 Mar;8(3):190-8
pubmed: 16611412
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13866-71
pubmed: 11698646
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
J Clin Pathol. 2006 Sep;59(9):972-7
pubmed: 16935972
Annu Rev Immunol. 2005;23:515-48
pubmed: 15771580
Int J Oncol. 2013 Jul;43(1):5-12
pubmed: 23673510
Hum Pathol. 2016 Jan;47(1):52-63
pubmed: 26527522
J Clin Oncol. 2006 Oct 1;24(28):4603-10
pubmed: 17008702
J Immunol. 2015 Feb 1;194(3):950-9
pubmed: 25539810
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
JAMA Oncol. 2015 Oct;1(7):888-96
pubmed: 26291673
Breast Cancer Res Treat. 2011 Aug;128(3):703-711
pubmed: 20842526
Clin Dev Immunol. 2013;2013:785317
pubmed: 23861693
Mod Pathol. 2015 Sep;28(9):1167-73
pubmed: 26111975
Ann Surg Oncol. 2012 Nov;19(12):3979-86
pubmed: 22622474
Ann Surg Oncol. 2019 Oct;26(10):3337-3343
pubmed: 31240590
Mod Pathol. 2016 Mar;29(3):249-58
pubmed: 26769139
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Expert Opin Biol Ther. 2016;16(5):619-26
pubmed: 26898656
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Science. 2015 Apr 3;348(6230):56-61
pubmed: 25838373